7th Annual Achieving Quality & Process Excellence in the Pharmaceutical Industry

Fleming Europe24 - 25 May 2011, Barcelona, Spain.
What are the new approaches to quality to achieve world-class manufacturing performance? How can you successfully introduce innovation and continual improvement into manufacturing?

Continuing pressures on life sciences manufacturing, from increased competition to regulatory requirements, are forcing organizations to achieve tighter operating efficiencies, while improving their ability to satisfy quality compliance standards.

Leading Pharma companies are now looking to Lean Manufacturing and Six Sigma principles to help them boost operational efficiency and improve quality. Explore the importance of six sigma in process validation and how to successfully apply Lean approach in Quality Assurance to simplify the processes.

Discuss with leading experts, how to build a sustainable quality culture during the times of change. Understand how to apply QbD tools during method development phase to achieve robust and reliable analytical procedures. Gain critical insights & first-hand experience how to incorporate risk management thinking and practices across the entire organization.

This event will bring together senior industry quality & operational excellence experts from the Pharmaceutical industry presenting real life case studies as well as a lot of networking sessions and discussions.

Key speakers:

  • Head of Quality Control, Sanofi Aventis, Germany
  • Senior Vice President Quality Assurance, Glenmark Pharmaceuticals, India
  • Head Operational Excellence & Lean, AstraZeneca, Sweden
  • Director Turbuhaler, AstraZeneca, Sweden
  • Quality Assurance Projects, Abbott, Italy
  • Head of Processes & Product Quality, Belupo, Croatia
  • More speakers to be announced

Key topics:

  • Explore Process Innovations for Operational Excellence
  • Enhance six sigma strategies to control costs, improve productivity and maintain compliance – how to integrate Quality & Operational Efficiency
  • Understand, how to link quality to performance
  • Reveal new approaches & tools for facilitating continuous improvement - building a sustainable quality culture and getting the right thinking across the entire organization
  • Maximize the benefits of QbD and Process understanding - best practices in QbD & PAT
  • Embrace Quality Risk Management - from theory to practice
  • Deployment of quality management for biologics - new challenges in aseptic processing of biologics
  • Understand new regulatory aspects of modern quality management and being prepared for the inspection

PLUS 3 Interactive Workshops:

  • Achieving efficiency in Quality Control
  • Application of Lean approach to Quality Assurance
  • Quality Risk Management - the new paradigm

Who should attend:
Vice Presidents, Heads, Directors, Senior Managers and Managers of: Quality Management, Quality Assurance, Quality Operations, Quality Control, Quality Systems, Regulatory Affairs, GMP Compliance, Quality by Design, PAT, Lean/Six Sigma, Lean Manufacturing, API manufacturing, Technical operations, Contract Manufacturing, Operational Excellence, Business Process Excellence, Operations, Production, Manufacturing, Supply Chain, Quality Risk Management, Qualified Person, Right First Time leaders.

For further information and registration, please visit:
http://flemingeurope.com/pharmaceuticals-conferences/europe/7th-annual-achieving-quality-process-excellence-in-the-pharmaceutical-industry

About Fleming Europe conferences
Fleming Europe conferences are events linking business with intelligence. Carefully designed to provide key strategic business information and the best networking opportunities for the participants, our B2B conferences are highly interactive. Number of delegates from specialized industry sectors - brought together by Fleming Europe - become part of a premium community discussing the questions of the day and enjoying the value of a five star event.

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...